Renal sympathetic nerve ablation for treatment-resistant hypertension

British Journal of Clinical Pharmacology

Volumn 76, Issue 4, 2013, Pages 495-503

  Krum, Henry ^a   Schlaich, Markus ^b   Sobotka, Paul ^c  

^a MONASH UNIVERSITY   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Denervation; Hypertension; Renal

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NORADRENALIN; RENIN;

ABLATION THERAPY; ADRENERGIC SYSTEM; ARTICLE; BLOOD PRESSURE REGULATION; CATHETER ABLATION; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; DIABETES MELLITUS; EFFERENT NERVE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; INSULIN RESISTANCE; KIDNEY BLOOD FLOW; KIDNEY DENERVATION; KIDNEY FUNCTION; KIDNEY INNERVATION; KIDNEY TUBULE ABSORPTION; MINIMALLY INVASIVE SURGERY; NERVE CONDUCTION; NONHUMAN; PERCUTANEOUS RENAL SYMPATHETIC NERVE DENERVATION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REINNERVATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; RESISTANT HYPERTENSION; RISK ASSESSMENT; SENSORY NERVE; SLEEP DISORDERED BREATHING; SODIUM RETENTION; SURGICAL TECHNIQUE; SYMPATHETIC NERVE; SYSTOLIC HEART FAILURE;

DENERVATION; HYPERTENSION; RENAL;

AFFERENT PATHWAYS; ANTIHYPERTENSIVE AGENTS; CATHETER ABLATION; DRUG RESISTANCE; EFFERENT PATHWAYS; HUMANS; HYPERTENSION; KIDNEY; SYMPATHECTOMY; TREATMENT OUTCOME;

EID: 84884680356     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12171     Document Type: Article

References (38)

1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM, American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: e510-526.
2. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008; 52: 1749-1757.
3. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011; 124: 1046-1058.
4. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, Oliveras A, Ruilope LM. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57: 898-902.
5. Garg JP, Elliott WJ, Folker A, Izhar M, Black HR, RUSH University Hypertension Service. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005; 18: 619-626.
6. Václavík J, Sedlák R, Plachy M, Navrátil K, Plásek J, Jarkovsky J, Václavík T, Husár R, Kociánová E, Táborsky M. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57: 1069-1075.
7. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol 2010; 298: R245-253.
8. Smith PA, Graham LN, Mackintosh AF, Stoker JB, Mary DA. Relationship between central sympathetic activity and stages of human hypertension. Am J Hypertens 2004; 17: 217-222.
9. Esler M, Jennings G, Korner P, Blombery P, Burke F, Willett I, Leonard P. Total, and organ-specific, noradrenaline plasma kinetics in essential hypertension. Clin Exp Hypertens A 1984; 6: 507-521.
10. Krum H, Sobotka P, Mahfoud F, Böhm M, Esler M, Schlaich M. Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation 2011; 123: 209-215.
11. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997; 77: 75-197.
12. DiBona GF. Sympathetic nervous system influences on the kidney. Role in hypertension. Am J Hypertens 1989; 2: 119S-124.
13. Katholi RE. Renal nerves in the pathogenesis of hypertension in experimental animals and humans. Am J Physiol 1983; 245: F1-14.
14. DiBona GF. Physiology in perspective: the wisdom of the body: neural control of the kidney. Am J Physiol 2005; 289: R633-641.
15. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25: 878-882.
16. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106: 1974-1979.
17. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1266 cases. J Am Med Assoc 1953; 152: 1501-1504.
18. Allen TR. Current status of lumbar sympathectomy. Am Surg 1976; 42: 89-91.
19. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-1281.
20. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-1909.
21. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932-934.
22. Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert G, Esler M, Schlaich MP. Substantial reduction in single sympathetic nerve fring after renal denervation in patients with resistant hypertension. Hypertension 2013; 61: 457-464.
23. Sobotka PA, Esler MD, Schlaich M, Schmieder RE, Böhm M, Krum H. Symplicity HTN-1: long-term follow-up of catheter-based renal sympathetic denervation for resistant hypertension confirms durable blood pressure reduction. Presented at ACC 2012, Chicago, IL.
24. Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA. Renal sympathetic denervation for treatment of drug-resistant hypertension: one year results from the Symplicity HTN-2 randomized controlled trial. Circulation 2012; 126: 2976-2982.
25. Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM, Katzen BT, Leon MB, Massaro JM, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend RR, Bakris G. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol 2012; 35: 528-535.
26. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Böhm M. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011; 123: 1940-1946.
27. Grassi G, Dell'Oro R, Quarti-Trevano F, Scopelliti F, Seravalle G, Paleari F, Gamba PL, Mancia G. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 2005; 48: 1359-1365.
28. Witkowski A, Prejbisz A, Florczak E, Kadziela J, Śliwiński P, Bieleń P, Michalowska I, Kabat M, Warchol E, Januszewicz M, Narkiewicz K, Somers VK, Sobotka PA, Januszewicz A. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58: 559-565.
29. Kasai T, Floras JS, Bradley TD. Sleep apnea and cardiovascular disease. A bidirectional relationship. Circulation 2012; 126: 1495-1510.
30. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Böhm M, Hoppe UC. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012; 59: 901-909.
31. Floras JS. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. J Am Coll Cardiol 1993; 22: (4 Suppl. A): 72A-84A.
32. Krum H. Sympathetic activation and the role of beta-blockers in chronic heart failure. Aust N Z J Med 1999; 29: 418-427.
33. Sobotka PA, Krum H, Böhm M, Francis DP, Schlaich MP. The role of renal denervation in the treatment of heart failure. Curr Cardiol Rep 2012; 14: 285-292.
34. Nozawa T, Igawa A, Fujii N, Kato B, Yoshida N, Asanoi H, Inoue H. Effects of long-term renal sympathetic denervation on heart failure after myocardial infarction in rats. Heart Vessels 2002; 16: 51-56.
35. Villarreal D, Freeman RH, Johnson RA, Simmons JC. Effects of renal denervation on postprandial sodium excretion in experimental heart failure. Am J Physiol 1994; 266: R1599-1604.
36. Davies JE, Manisty CH, Petraco R, Barron AJ, Unsworth B, Mayet J, Hamady M, Hughes AD, Sever PS, Sobotka PA, Francis DP. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol 2013; 162: 189-192.
37. Symplicity HF trial. Available at http://clinicaltrials.gov/ct2/show/study/NCT01392196?term=krum&rank=10 (last accessed 19 September 2012).
38. Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, Sobotka PA, Böhm M, Cremers B, Esler MD, Schlaich MP. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012; 23: 1250-1257.